Apple announces iPhone 17 with 48MP cameras and 6.3-inch display
DUBLIN - Perrigo Company plc (NYSE: NYSE:PRGO), a global leader in consumer self-care products, has announced a 5% increase in its quarterly dividend. The new dividend rate will be $0.290 per share, amounting to $1.16 annually, up from the previous $0.276 per share. With the stock currently trading at $24.63, this represents a 4.7% dividend yield. This increment continues the company’s 22-year streak of consecutive dividend increases, as confirmed by InvestingPro data.
The upcoming cash dividend is scheduled for payment on March 25, 2025, to shareholders on record as of March 7, 2025. Perrigo has a long-standing history of providing over-the-counter health and wellness solutions that empower consumers to manage their health proactively. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 2.56, while trading near its 52-week low, suggesting potential value opportunity.
This dividend announcement is a forward-looking statement subject to various risks and uncertainties, including those related to future dividend payments. Perrigo advises interested parties to review their filings with the Securities and Exchange Commission, which detail the company’s business, financial condition, and potential risks.
The information in this article is based on a press release statement from Perrigo Company plc.
In other recent news, Perrigo Company plc has announced several significant developments. The company has reached a $98 million settlement in a long-standing insurance dispute related to securities litigation from 2015 to 2017. This settlement will be received before the end of the fiscal year, aiding in offsetting legal expenses and settlement costs. Additionally, Perrigo has appointed Abbie Lennox as the new Chief Scientific Officer, following her successful tenure at Bayer (OTC:BAYRY) Consumer Health. Lennox’s appointment is part of a strategic move to enhance collaboration and innovation within the company’s product portfolio. In another update, Piper Sandler has downgraded Perrigo’s stock rating from Overweight to Neutral, citing concerns over the infant formula segment and potential pressures on the company’s financial model. The firm has adjusted the price target to $27.00, reflecting a more conservative outlook. Furthermore, Katherine Doyle, an independent board member, will retire after the 2025 annual general meeting, marking a period of transition for the board. These recent developments underscore Perrigo’s ongoing strategic shifts and financial adjustments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.